Durezol, (difluprednate ophthalmic emulsion) is the latest medicine developed to treat postoperative ocular inflammation and other inflammatory eye diseases.
This topical anti-inflammatory ophthalmic steroid was approved by the US Food and Drug Administration (FDA) on June 28, 2008, and Sirion terapeutic Inc., the company that will represent the drug, intends to initiate its at the end of the same year.
This medication is indicated to reduce the inflammation and the pain especially in the postoperative ophtalmological, reducing the risk of complications and significantly improving the prognosis and recovery of the patient.
